Hims & Hers Health Inc. (NYSE: HIMS) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud related to misleading statements made to investors during a specified Class Period [1][2]. Group 1: Investigation Details - Berger Montague is investigating Hims & Hers for possible violations of federal securities laws during the Class Period from April 29, 2025, to June 22, 2025 [1]. - The investigation follows a significant drop in Hims & Hers' stock price, which fell over 34% after Novo Nordisk terminated its partnership due to unauthorized marketing and sale of compounded semaglutide drugs [2]. - A complaint has been filed alleging that Hims & Hers made material misstatements and omissions, violating federal securities laws [2]. Group 2: Legal Actions - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to direct the case and advocate for other affected investors [3].